Whereas up to 2,400,000 individuals in the United States are chronically infected with hepatitis B, and up to 2/3 of individuals with chronic hepatitis B are unaware of their infection; Whereas hepatitis B is a viral infection of the liver transmitted via infected blood and other bodily fluids, including through mother-to-child transmission and injection drug use; Whereas hepatitis B is associated with significant disparities among communities of color (including Asian Americans, Pacific Islanders, and African immigrants), sexual and gender minority communities, and those affected by the opioid crisis; Whereas individuals with chronic diseases, such as diabetes, HIV, hepatitis C, and chronic liver disease, and individuals on hemodialysis are at an increased risk for hepatitis B co-infection; Whereas there is no cure for hepatitis B, and individuals with chronic hepatitis B require lifelong medical care; Whereas chronic hepatitis B represents 1 of the most common causes of liver cancer; Whereas 1 in every 4 individuals with unmanaged chronic hepatitis B will develop liver cancer, cirrhosis, or liver failure, with liver cancer having a 5-year survival rate of only 18 percent in the United States; Whereas safe and highly effective vaccines to protect against hepatitis B are available; Whereas, in accordance with universal childhood hepatitis B vaccination recommendations in the United States, infants and children have been routinely vaccinated against hepatitis B since the 1990s; Whereas all adults between 19 and 59 years of age, and adults 60 and older who have hepatitis B risk factors, are recommended to be vaccinated against hepatitis B; Whereas the hepatitis B vaccine, which is 95 percent effective and was the first anticancer vaccine to be developed, is projected to have prevented 310,000,000 cases of hepatitis B worldwide from 1990 to 2020; Whereas only 30 percent of adults in the United States are vaccinated against hepatitis B